Ixekizumab in the Treatment of Bullous Pemphigoid

Summary

Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.

Timeline

Start

2017-08-15

Primary completion

2019-06-06

Completion

2019-06-06

Drugs

Indications